+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Intermittent Claudication - Pipeline Review, H1 2020

  • ID: 4911667
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 55 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Helixmith Co Ltd
  • ID Pharma Co Ltd
  • Novartis AG
  • MORE
Intermittent Claudication - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication - Pipeline Review, H1 2020, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape.

Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Intermittent Claudication - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Intermittent Claudication (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Intermittent Claudication (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Intermittent Claudication (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Intermittent Claudication (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Intermittent Claudication (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Helixmith Co Ltd
  • ID Pharma Co Ltd
  • Novartis AG
  • MORE
  • Introduction
  • Report Coverage
  • Intermittent Claudication - Overview
  • Intermittent Claudication - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Intermittent Claudication - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Intermittent Claudication - Companies Involved in Therapeutics Development
  • G. Pohl-Boskamp GmbH & Co KG
  • Helixmith Co Ltd
  • ID Pharma Co Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Intermittent Claudication - Drug Profiles
  • DVC-10101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • emiplacel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Cardiovascular, Dermatology and Neurology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LLG-783 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitroglycerin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Intermittent Claudication - Dormant Projects
  • Intermittent Claudication - Discontinued Products
  • Intermittent Claudication - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Intermittent Claudication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Intermittent Claudication - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2020
  • Intermittent Claudication - Pipeline by Helixmith Co Ltd, H1 2020
  • Intermittent Claudication - Pipeline by ID Pharma Co Ltd, H1 2020
  • Intermittent Claudication - Pipeline by Novartis AG, H1 2020
  • Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc, H1 2020
  • Intermittent Claudication - Dormant Projects, H1 2020
  • Intermittent Claudication - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Intermittent Claudication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • G. Pohl-Boskamp GmbH & Co KG
  • Helixmith Co Ltd
  • ID Pharma Co Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll